IP Library › Granted Patent US 9,932,561
Granted Patent B2
US 9,932,561 · App. 14/340,161 · Granted Apr 3, 2018

Differentiating induced pluripotent stem cells into glucose-responsive, insulin-secreting progeny

Inventors: Tayaramma Thatava (Blue Ash, OH); Andre Terzic (Rochester, MN); Yogish C. Kudva (Rochester, MN); Yasuhiro Ikeda (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research
C12N5/0696C12N5/0677C12N2500/46C12N2500/90C12N2500/98C12N2500/99C12N2501/119C12N2501/16C12N2501/335C12N2501/385C12N2501/41C12N2501/415C12N2501/60C12N2501/603C12N2501/605C12N2501/606C12N2501/608C12N2501/727C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,932,561
App. No.
14/340,161
Granted
Apr 3, 2018
Kind
B2
Abstract

This document provides methods and materials related to differentiating iPS cells into glucose-responsive, insulin-secreting progeny. For example, methods and material for using indolactam V (ILV) and glucagon like peptide-1 (GLP-1) to produce glucose-responsive, insulin-secreting progeny from iPS cells are provided.

Claims (12)

1. A method for obtaining a population of glucose-responsive, insulin-secreting cells from a diabetic human, wherein said method comprises:

(a) obtaining somatic cells from a diabetic human,

(b) exposing said somatic cells to one or more polypeptides or nucleic acids encoding said one or more polypeptides to form induced pluripotent stem cells, wherein said one or more polypeptides are selected from the group consisting of a Oct3/4 polypeptide, a Sox family polypeptide, a Klf family polypeptide, a Myc family polypeptide, a Nanog polypeptide, and a Lin28 polypeptide, and

(c) culturing said induced pluripotent stem cells with medium comprising indolactam V and glucagon like peptide-1 to obtain said population of glucose-responsive, insulin-secreting cells.

2. The method of claim 1 , wherein said medium lacks serum.

3. The method of claim 1 , wherein said culturing is performed in the absence of feeder cells.

4. The method of claim 1 , wherein said culturing is performed in the absence of non-human feeder cells.

5. The method of claim 1 , wherein said somatic cells are selected from the group consisting of skin, lung, heart, stomach, brain, liver, blood, kidney, and muscle cells.

6. The method of claim 1 , wherein said induced pluripotent stem cells comprise exogenous nucleic acid encoding a human Oct4 polypeptide, a human Sox2 polypeptide, a human Klf4 polypeptide, and a human c-Myc polypeptide.

7. The method of claim 1 , wherein said medium comprises greater than 300 nM of indolactam V.

8. The method of claim 1 , wherein said medium comprises greater than 55 nM of glucagon like peptide-1.

9. The method of claim 1 , wherein said culturing is performed for four days.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2014
From: IKEDA, YASUHIRO
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 033759/0020 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2014
From: THATAVA, TAYARAMMA; TERZIC, ANDRE; KUDVA, YOGISH C.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 033583/0103 →
Continuity (3)
Continuation 13553064 · Jul 19, 2012
Provisional Application 61510818 · Jul 22, 2011
Related Publication 20140356951A1 · Dec 4, 2014